" class="no-js "lang="en-US"> Dunad Therapeutics - Medtech Alert
Tuesday, March 19, 2024
Dunad Therapeutics | Pharmtech Focus

Dunad Therapeutics

About Dunad Therapeutics

Dunad Therapeutics

Dunad Therapeutics is a biopharmaceutical company focusing on the development of next-generation targeted oral protein degradation therapies. Dunad’s platform enables selective degradation via direct target modification using tunable mono-valent small molecules, allowing for the development of more drug-like, orally bioavailable and CNS-accessible protein degraders.

Related Story

Dunad Therapeutics Appoints Industry Veteran Pearl Huang as Chief Executive Officer

June 29 2022

Dunad Therapeutics, a biopharmaceutical company developing small molecule covalent therapies based on novel insights from […]

Dunad Therapeutics Enters Strategic Collaboration with Novartis to Develop Next-generation Oral Targeted Protein Degrader Therapies

November 2 2021

Dunad Therapeutics (“Dunad”), a biopharmaceutical company focusing on the development of next-generation targeted protein degradation […]